Welcome to CDC Stacks | Hospital Associated-Venous Thromboembolism (HA-VTE) Stakeholder Meeting, September 21, 2012, Atlanta, GA : meeting summary - 44516 | Stephen B. Thacker CDC Library collection
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Hospital Associated-Venous Thromboembolism (HA-VTE) Stakeholder Meeting, September 21, 2012, Atlanta, GA : meeting summary
  • Published Date:
    1/6/14
  • Language:
    English
Filetype[PDF - 1.02 MB]


Details:
  • Corporate Authors:
    National Center on Birth Defects and Developmental Disabilities (Centers for Disease Control and Prevention (U.S.)). Division of Blood Disorders.
  • Conference Authors:
    Hospital Associated-Venous Thromboembolism (HA-VTE) Stakeholder Meeting (September 21, 2012 : Atlanta, GA)
  • Description:
    Venous thromboembolism (VTE) includes both deep vein thrombosis (DVT) and pulmonary embolism (PE), and is an important and growing public health issue. DVT is a blood clot that forms in the deep veins of the body and PE occurs when a clot breaks free and blocks the arteries of the lungs. The precise number of people affected by VTE is unknown; however, estimates suggest that 350,000 to 900,000 events occur in the United States yearly with healthcare costs ranging from $1 billion to $10 billion. VTE is associated with substantial health impacts including mortality. In the United States, it is estimated that as many as 100,000 people die of PE each year. With many of the risks for VTE, such as obesity, advanced age, and chronic diseases increasing in the US population, we can expect to see increasing numbers of people affected by VTE.

    Fortunately, many cases of VTE can be prevented and, in those that occur, poor outcomes may be preventable with early and accurate diagnosis and management. However, one of the major challenges for preventing VTE is the ability to effectively predict which individuals are at greatest risk and ensure that appropriate prevention measures are taken. People who have recently been hospitalized or those who have had surgery, have an increased risk of developing VTE. The application of appropriate prevention steps during and after hospitalization among these individuals at high risk can result in a significant reduction in overall VTE occurrence, healthcare burden, and death. Prevention of hospital- associated VTE (HA-VTE) is a national priority. It is a Healthy People 2020 objective and a key component of the U.S. Department of Health and Human Services Partnerships for Patients Initiative. Other federal agencies including the Centers for Medicare and Medicaid Services (CMS) and the Agency for Healthcare Research and Quality (AHRQ) as well as national organizations such as The Joint Commission, National Quality Forum, American College of Surgeons, and others have initiated programs and activities focusing on HA-VTE prevention.

    The Division of Blood Disorders (DBD), National Center on Birth Defects and Developmental Disabilities (NCBDDD), Centers for Disease Control and Prevention (CDC) convened a stakeholder meeting on September 21, 2012 in Atlanta, Georgia to inform the development of and assess the need for HA-VTE surveillance.

    CS243316

    Publication date from document properties.

    surveillancestakeholdermeetingsummary_9212013.pdf

  • Supporting Files:
    No Additional Files